The dipeptide Phe-Phe amide attenuates signs of hyperalgesia, allodynia and nociception in diabetic mice using a mechanism involving the sigma receptor system

Molecular Pain

Volumn 7, Issue , 2011, Pages

  Ohsawa, Masahiro ^a   Carlsson, Anna ^b   Asato, Megumi ^a   Koizumi, Takayuki ^a   Nakanishi, Yuki ^a   Fransson, Rebecca ^b   Sandström, Anja ^b   Hallberg, Mathias ^b   Nyberg, Fred ^b   Kamei, Junzo ^a  

^a HOSHI UNIVERSITY   (Japan)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

1 receptor; Allodynia; Antinociception; Diabetes; Hyperalgesia; Opioid receptors; Phe phe amide; Substance p1 7

Indexed keywords

DIPEPTIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PENTAZOCINE; PHENYLALANYLPHENYLALANYLAMIDE; SIGMA 1 OPIATE RECEPTOR; UNCLASSIFIED DRUG; SIGMA OPIATE RECEPTOR;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG MECHANISM; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HYPERALGESIA; MALE; MOUSE; NOCICEPTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TAIL FLICK TEST; ANIMAL; DRUG EFFECT; DRUG POTENTIATION; EXPERIMENTAL DIABETES MELLITUS; GENETICS; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; DIABETES MELLITUS, EXPERIMENTAL; DIPEPTIDES; HYPERALGESIA; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED ICR; NOCICEPTION; PENTAZOCINE; PHOSPHORYLATION; RECEPTORS, SIGMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 80055001170     PISSN: None     EISSN: 17448069     Source Type: Journal    
DOI: 10.1186/1744-8069-7-85     Document Type: Article

References (47)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053. 10.2337/diacare.27.5.1047, 15111519.
2. Feldman EL, Russell JW, Sullivan KA, Golovoy D. New insights into the pathogenesis of diabetic neuropathy. Curr Opin Neurol 1999, 12:553-563. 10.1097/00019052-199910000-00009, 10590892.
3. Dyck PJ, Dyck PJ, Larson TS, O'Brien PC, Velosa JA. Patterns of quantitative sensation testing of hypoesthesia and hyperalgesia are predictive of diabetic polyneuropathy: a study of three cohorts. Nerve growth factor study group. Diabetes Care 2000, 23:510-517. 10.2337/diacare.23.4.510, 10857944.
4. Kingery WS. A critical review of controlled clinical trrials for peripheral neuropathic pain and complex regional pain syndromes. Pain 1990, 73:123-139.
5. Carlsson A, Ohsawa M, Hallberg M, Nyberg F, Kamei J. Substance P(1-7) induces antihyperalgesia in diabetic mice through a mechanism involving the naloxone-sensitive sigma receptors. Eur J Pharmacol 2010, 626:250-255. 10.1016/j.ejphar.2009.10.006, 19836387.
6. von Euler US, Gaddum JH. An unidentified depressor substance in certain tissue extracts. J Physiol 1931, 72:74-87. 1403098, 16994201.
7. Hökfelt T, Pernow B, Wahren J. Substance P: a pioneer amongst neuropeptides. J Int Med 2001, 249:27-40.
8. Hall ME, Stewart JM. Substance P and Behavior: Opposite effects of N-terminal and C-terminal fragments. Peptides 1983, 4:763-768. 10.1016/0196-9781(83)90033-5, 6197702.
9. Hallberg M, Nyberg F. Neuropeptide conversion to bioactive fragments - an important Pathway in neuromodulation. Curr Prot Pept Sci 2003, 4:31-44.
10. Sakurada T, Le Grevès P, Stewart J, Terenius L. Measurement of Substance P metabolites in rat CNS. J Neurochem 1985, 44:718-722. 10.1111/j.1471-4159.1985.tb12874.x, 2579196.
11. Stewart JM, Hall ME, Harkins J, Frederickson RCA, Terenius L, Hökfelt T, Krivoy WA. A fragment of substance P with specific activity: SP(1-7). Peptides 1982, 3:851-857. 10.1016/0196-9781(82)90027-4, 6184702.
12. Wiktelius D, Khalil Z, Nyberg F. Modulation of peripheral inflammation by the substance P N-terminal metabolite substance P1-7. Peptides 2006, 27:1490-1497. 10.1016/j.peptides.2005.12.004, 16414148.
13. Kreeger JS, Larson AA. The Substance P amino-terminal metabolite Substance P(1-7), administered peripherally, prevents the development of acute morphine tolerance and attenuates the expression of withdrawal in mice. J Pharmacol Exp Ther 1996, 279:662-667.
14. Zhou Q, Nyberg F. Injection of substance P (SP) N-terminal fragment SP(1-7) into the ventral tegmental area modulates the levels of nucleus accumbens dopamine and dihydroxyphenylacetic acid in male rats during morphine withdrawal. Neurosci Lett 2002, 320:117-120. 10.1016/S0304-3940(01)02564-2, 11852176.
15. Botros M, Hallberg M, Johansson T, Zhou Q, Lindeberg G, Frändberg PA, Tömböly C, Tóth G, Le Grevès P, Nyberg F. Endomorphin-1 and endomorphin-2 differentially interact with specific binding sites for substance P (SP) aminoterminal SP1-7 in the rat spinal cord. Peptides 2006, 27:753-759. 10.1016/j.peptides.2005.08.009, 16216386.
16. Igwe OJ, Kim DC, Seybold VS, Larson AA. Specific binding of substance P aminoterminal heptapeptide [SP(1-7)] to mouse brain and spinal cord membranes. J Neurosci 1990, 10:3653-3663.
17. Botros M, Johansson T, Zhou Q, Lindeberg G, Tömböly C, Tóth G, Le Grevès P, Nyberg F, Hallberg M. Endomorphins interact with the substance P (SP) aminoterminal SP1-7 binding in the ventral tegmental area of the rat brain. Peptides 2008, 29:1820-1824. 10.1016/j.peptides.2008.05.014, 18597894.
18. Ohsawa M, Carlsson A, Asato M, Koizumi T, Nakanishi Y, Fransson R, Sandström A, Hallberg M, Nyberg F, Kamei J. The effect of substance P1-7 amide on nociceptive threshold in diabetic mice. Peptides 2011, 32:93-98. 10.1016/j.peptides.2010.09.029, 20933559.
19. Zhou Q, Carlsson A, Botros M, Fransson R, Sandström A, Gordh T, Hallberg M, Nyberg F. The C-terminal amidated analogue of the substance P (SP) fragment SP(1-7) attenuates the expression of naloxone-precipitated withdrawal in morphine dependent rats. Peptides 2009, 30:2418-2422. 10.1016/j.peptides.2009.08.009, 19686790.
20. Hornfeldt CS, Kitto KF, Larson AA. Evidence that the NH2-terminus of substance P modulates N-methyl-D-aspartate-induced activity by an action involving σ receptors. Eur J Pharmacol 1996, 306:15-22. 10.1016/0014-2999(96)00199-9, 8813610.
21. Larson AA, Sun X. Modulation of kainic acid-induced activity in the mouse spinal cord by the amino terminus of substance P: sensitivity to opioid antagonists. J Pharmacol Exp Ther 1993, 265:159-165.
22. de la Puente B, Nadal X, Portillo-Salido E, Sánchez-Arroyos R, Ovalle S, Palacios G, Muro A, Romero L, Entrena JM, Baeyens JM, López-García JA, Maldonado R, Zamanillo D, Vela JM. Sigma-1 receptors regulate activity-induced spinal sensitization and neuropathic pain after peripheral nerve injury. Pain 2009, 145:294-303. 10.1016/j.pain.2009.05.013, 19505761.
23. Fransson R, Botros M, Nyberg F, Lindeberg G, Sandström A, Hallberg M. Small peptides mimicking substance P (1-7) and encompassing a C-terminal amide functionality. Neuropeptides 2008, 42:31-37. 10.1016/j.npep.2007.11.002, 18093649.
24. Fransson R, Botros M, Sköld C, Nyberg F, Lindeberg G, Hallberg M, Sandström A. Discovery of dipeptides with high affinity to the specific binding site for substance P1-7. J Med Chem 2010, 53:2383-2389. 10.1021/jm901352b, 20178322.
25. Fontanilla D, Johannessen M, Hajipour AR, Cozzi NV, Jackson MB, Ruoho AE. The hallucinogen N, N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science 2009, 323:934-937. 10.1126/science.1166127, 2947205, 19213917.
26. Tsao LI, Su TP. Naloxone-sensitive, haloperidol-sensitive, [3H](+)SKF-10047-binding protein partially purified from rat liver and rat brain membranes: an opioid/sigma receptor?. Synapse 1997, 25:117-124. 10.1002/(SICI)1098-2396(199702)25:2<117::AID-SYN2>3.0.CO;2-F, 9021892.
27. Kim HW, Roh DH, Yoon SY, Seo HS, Kwon YB, Han HJ, Kim KW, Beitz AJ, Lee JH. Activation of the spinal sigma-1 receptor enhances NMDA-induced pain via PKC- and PKA-dependent phosphorylation of the NR1 subunit in mice. Br J Pharmacol 2008, 154:1125-1134. 10.1038/bjp.2008.159, 2465573, 18493253.
28. Baron R. Mechanisms of disease: neuropathic pain-a clinical perspective. Nat Clin Pract Neurol 2006, 2:95-106. 10.1038/ncpneuro0113, 16932531.
29. Meller ST, Dykstra CL, Gebhart GF. Investigations of the possible role for carbon monoxide (CO) in thermal and mechanical hyperalgesia in the rat. Neuroreport 1994, 5:2337-2341. 10.1097/00001756-199411000-00032, 7881055.
30. Nieto FR, Entrena JM, Cendán CM, Pozo ED, Vela JM, Baeyens JM. Tetrodotoxin inhibits the development and expression of neuropathic pain induced by paclitaxel in mice. Pain 2008, 137:520-531. 10.1016/j.pain.2007.10.012, 18037242.
31. Treede RD, Meyer RA, Raja SN, Campbell JN. Peripheral and central mechanisms of cutaneous hyperalgesia. Prog Neurobiol 1992, 38:397-421. 10.1016/0301-0082(92)90027-C, 1574584.
32. Ola MS, Moore P, Maddox D, El-Sherbeny A, Huang W, Roon P, Agarwal N, Ganapathy V, Smith SB. Analysis of sigma receptor (sigmaR1) expression in retinal ganglion cells cultured under hyperglycemic conditions and in diabetic mice. Brain Res Mol Brain Res 2002, 107:97-107.
33. Mardon K, Kassiou M, Donald A. Effects of streptozotocin-induced diabetes on neuronal sigma receptors in the rat brain. Life Sci 1999, 65:PL281-PL286.
34. Bergeron R, de Montigny C, Debonnel G. Potentiation of neuronal NMDA response induced by dehydroepiandrosterone and its suppression by progesterone: effects mediated via sigma receptors. J Neurosci 1996, 16:1193-1202.
35. Hayashi T, Kagaya A, Takebayashi M, Shimizu M, Uchitomi Y, Motohashi N, Yamawaki S. Modulation by sigma ligands of intracellular free Ca++ mobilization by N-methyl-D-aspartate in primary culture of rat frontal cortical neurons. J Pharmacol Exp Ther 1995, 275:207-214.
36. Martina M, Turcotte ME, Halman S, Bergeron R. The sigma-1 receptor modulates NMDA receptor synaptic transmission and plasticity via SK channels in rat hippocampus. J Physiol 2007, 578:143-157. 2075134, 17068104.
37. Monnet FP, Debonnel G, Junien JL, De Montigny C. N-methyl-D-aspartate-induced neuronal activation is selectively modulated by sigma receptors. Eur J Pharmacol 1990, 179:441-445. 10.1016/0014-2999(90)90186-A, 2163857.
38. Monnet FP, Morin-Surun MP, Leger J, Combettes L. Protein kinase C-dependent potentiation of intracellular calcium influx by sigma1 receptor agonists in rat hippocampal neurons. J Pharmacol Exp Ther 2003, 307:705-712. 10.1124/jpet.103.053447, 12975497.
39. Monnet FP. Sigma-1 receptor as regulator of neuronal intracellular Ca2+: clinical and therapeutic relevance. Biol Cell 2005, 97:873-883.
40. Su TP, Hayashi T. Understanding the molecular mechanism of sigma-1 receptors: towards a hypothesis that sigma-1 receptors are intracellular amplifiers for signal transduction. Curr Med Chem 2003, 10:2073-2080. 10.2174/0929867033456783, 12871086.
41. Kawasaki Y, Kohno T, Zhuang ZY, Brenner GJ, Wang H, Van Der Meer C, Befort K, Woolf CJ, Ji RR. Ionotropic and metabotropic receptors, protein kinase A, protein kinase C, and Src contribute to C-fiber-induced ERK activation and cAMP response element-binding protein phosphorylation in dorsal horn neurons, leading to central sensitization. J Neurosci 2004, 24:8310-8321. 10.1523/JNEUROSCI.2396-04.2004, 15385614.
42. Zhuang ZY, Gerner P, Woolf CJ, Ji RR. ERK is sequentially activated in neurons, microglia, and astrocytes by spinal nerve ligation and contributes to mechanical allodynia in this neuropathic pain model. Pain 2005, 114:149-159. 10.1016/j.pain.2004.12.022, 15733640.
43. D'amour FE, Smith DL. A method for determining loss of pain sensation. J Pharmacol Exp Ther 1941, 72:74-79.
44. Ohsawa M, Kamei J. Possible involvement of spinal protein kinase C in thermal allodynia and hyperalgesia in diabetic mice. Eur J Pharmacol 1999, 372:221-228. 10.1016/S0014-2999(99)00228-9, 10395015.
45. Hylden JL, Wilcox GL. Intrathecal morphine in mice: a new technique. Eur J Pharmacol 1980, 67:313-316. 10.1016/0014-2999(80)90515-4, 6893963.
46. Kamei J, Iwamoto Y, Misawa M, Nagase H, Kasuya Y. Antinociceptive effect of L-arginine in diabetic mice. Eur J Pharmacol 1994, 254:113-117. 10.1016/0014-2999(94)90377-8, 8206107.
47. Wu HE, Hong JS, Tseng LF. Stereoselective action of (+)-morphine over (-)-morphine in attenuating the (-)-morphine-produced antinociception via the naloxone-sensitive sigma receptor in the mouse. Eur J Pharmacol 2007, 571:145-151. 10.1016/j.ejphar.2007.06.012, 2080825, 17617400.